LATS2 and malignant mesothelioma: Towards this goal we investigated YAP1 binding in NCI-H2052 malignant mesothelioma cells, a cell line of different lineage and with a different mechanism of YAP1 activation (NF2 mutation, LATS2 deletion) [63].